Cencora, Inc. (NYSE:COR) Shares Purchased by Insight Wealth Strategies LLC

Insight Wealth Strategies LLC boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 124.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,249 shares of the company's stock after buying an additional 11,232 shares during the quarter. Insight Wealth Strategies LLC's holdings in Cencora were worth $4,549,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its position in shares of Cencora by 6,855.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after buying an additional 2,035,679 shares in the last quarter. Bank of Montreal Can lifted its holdings in Cencora by 136.8% during the second quarter. Bank of Montreal Can now owns 641,887 shares of the company's stock valued at $153,623,000 after purchasing an additional 370,841 shares in the last quarter. American Century Companies Inc. grew its position in shares of Cencora by 155.0% in the second quarter. American Century Companies Inc. now owns 598,438 shares of the company's stock valued at $134,828,000 after purchasing an additional 363,796 shares during the period. Wellington Management Group LLP increased its stake in shares of Cencora by 7.0% during the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock worth $1,168,927,000 after purchasing an additional 338,452 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Cencora by 40.2% during the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock worth $243,173,000 after purchasing an additional 308,773 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Activity

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the firm's stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company's stock, valued at approximately $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 94,696 shares of company stock valued at $22,862,734 in the last quarter. Insiders own 15.80% of the company's stock.

Analysts Set New Price Targets

COR has been the topic of several research analyst reports. Bank of America reiterated a "neutral" rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Evercore ISI boosted their price target on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. UBS Group raised their price objective on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Wells Fargo & Company lowered their target price on shares of Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a research note on Friday, December 13th. Finally, StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus price target of $275.60.

Cencora Trading Down 0.2 %

Shares of Cencora stock traded down $0.51 during mid-day trading on Monday, hitting $228.69. The stock had a trading volume of 1,005,821 shares, compared to its average volume of 1,152,907. The firm has a market cap of $44.20 billion, a P/E ratio of 30.45, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a 50-day moving average of $237.44 and a two-hundred day moving average of $233.60. Cencora, Inc. has a 12-month low of $208.58 and a 12-month high of $253.27.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.55 per share. This is a boost from Cencora's previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.96%. Cencora's dividend payout ratio (DPR) is 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.